TD 8236
Alternative Names: TD-8236Latest Information Update: 03 Mar 2023
At a glance
- Originator Theravance Biopharma
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Asthma
Most Recent Events
- 03 Mar 2023 TD 8236 is available for licensing as of 27 Feb 2023. https://www.theravance.com/
- 13 May 2022 Updated pharmacodynamics and adverse events data from a phase I trial in Asthma presented at the 118th International Conference of the American Thoracic Society(ATS-2022)
- 05 Sep 2021 Updated pharmacodynamics and pharmacokinetics data from a phase I trial in Healthy volunteers and Asthma presented at the 31st Annual Congress of the European Respiratory Society (ERS-2021)